Secondary Hyperparathyroidism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Secondary hyperparathyroidism occurs when the parathyroid glands in the neck produce too much parathyroid hormone (PTH) because calcium levels are too low. Symptoms include bone deformities, broken bones, swollen joints, and chronic kidney failure. Treatment includes calcimimetic and hormone replacement therapy.
The Secondary Hyperparathyroidism drugs in development market research report provide comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects.
Key Targets in the Secondary Hyperparathyroidism Pipeline Products Market
The key targets in the Secondary Hyperparathyroidism pipeline products market are Calcium Sensing Receptor, Vitamin D Receptor, Extracellular Calcium Sensing Receptor, 1,25-Dihydroxyvitamin D3 24-Hydroxylase Mitochondrial Cytochrome P450 24A1 or Cytochrome P450 CC24 or Vitamin D, and Inositol Hexakisphosphate and Diphosphoinositol Pentakisphosphate Kinase 1.
Secondary Hyperparathyroidism Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Secondary Hyperparathyroidism Pipeline Products Market
The key mechanisms of action in the Secondary Hyperparathyroidism pipeline products market are Calcium Sensing Receptor Agonist, Vitamin D Receptor Agonist, 1,25-Dihydroxyvitamin D3 24-Hydroxylase Mitochondrial Cytochrome P450 24A1 or Cytochrome P450 CC24 or Vitamin D Inhibitor, and Inositol Hexakisphosphate and Diphosphoinositol Pentakisphosphate Kinase 1 Inhibitor.
Secondary Hyperparathyroidism Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Secondary Hyperparathyroidism Pipeline Products Market
The key routes of administration in the Secondary Hyperparathyroidism pipeline products market are oral, intravenous, parenteral, and transdermal.
Secondary Hyperparathyroidism Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Secondary Hyperparathyroidism Pipeline Products Market
The key molecule types in the Secondary Hyperparathyroidism pipeline products market are small molecule, peptide, and synthetic peptide.
Secondary Hyperparathyroidism Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Secondary Hyperparathyroidism Pipeline Products Market
The major companies in the Secondary Hyperparathyroidism pipeline products market are OPKO Health Inc, Shaanxi Micot Technology Co Ltd, Amgen Inc, Cinkate Corp, Jiangsu Hengrui Medicine Co Ltd, Mitsubishi Tanabe Pharma Corp, Novadiol Inc, Scohia Pharma Inc, TaiRx Inc, and Vidasym Inc.
Secondary Hyperparathyroidism Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
Key targets | Calcium Sensing Receptor, Vitamin D Receptor, Extracellular Calcium Sensing Receptor, 1,25-Dihydroxyvitamin D3 24-Hydroxylase Mitochondrial Cytochrome P450 24A1 or Cytochrome P450 CC24 or Vitamin D, and Inositol Hexakisphosphate and Diphosphoinositol Pentakisphosphate Kinase 1 |
Key mechanism of action | Calcium Sensing Receptor Agonist, Vitamin D Receptor Agonist, 1,25-Dihydroxyvitamin D3 24-Hydroxylase Mitochondrial Cytochrome P450 24A1 or Cytochrome P450 CC24 or Vitamin D Inhibitor, and Inositol Hexakisphosphate and Diphosphoinositol Pentakisphosphate Kinase 1 Inhibitor |
Key routes of administration | Oral, Intravenous, Parenteral, and Transdermal |
Key molecule type | Small Molecule, Peptide, and Synthetic Peptide |
Major companies | OPKO Health Inc, Shaanxi Micot Technology Co Ltd, Amgen Inc, Cinkate Corp, Jiangsu Hengrui Medicine Co Ltd, Mitsubishi Tanabe Pharma Corp, Novadiol Inc, Scohia Pharma Inc, TaiRx Inc, and Vidasym Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism (Hormonal Disorders).
- The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Cinkate Corp
Jiangsu Hengrui Medicine Co Ltd
Mitsubishi Tanabe Pharma Corp
Novadiol Inc
OPKO Health Inc
Scohia Pharma Inc
Shaanxi Micot Technology Co Ltd
TaiRx Inc
Vidasym Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Secondary Hyperparathyroidism products market?
The key targets in the Secondary Hyperparathyroidism pipeline products market are Calcium Sensing Receptor, Vitamin D Receptor, Extracellular Calcium Sensing Receptor, 1,25-Dihydroxyvitamin D3 24-Hydroxylase Mitochondrial Cytochrome P450 24A1 or Cytochrome P450 CC24 or Vitamin D, and Inositol Hexakisphosphate and Diphosphoinositol Pentakisphosphate Kinase 1.
-
What are the key mechanisms of action in the Secondary Hyperparathyroidism pipeline products market?
The key mechanisms of action in the Secondary Hyperparathyroidism pipeline products market are Calcium Sensing Receptor Agonist, Vitamin D Receptor Agonist, 1,25-Dihydroxyvitamin D3 24-Hydroxylase Mitochondrial Cytochrome P450 24A1 or Cytochrome P450 CC24 or Vitamin D Inhibitor, and Inositol Hexakisphosphate and Diphosphoinositol Pentakisphosphate Kinase 1 Inhibitor.
-
What are the key routes of administration in the Secondary Hyperparathyroidism pipeline products market?
The key routes of administration in the Secondary Hyperparathyroidism pipeline products market are oral, intravenous, parenteral, and transdermal.
-
What are the key molecule types in the Secondary Hyperparathyroidism pipeline products market?
The key molecule types in the Secondary Hyperparathyroidism pipeline products market are small molecule, peptide, and synthetic peptide.
-
Which are the major companies in the Secondary Hyperparathyroidism pipeline products market?
The major companies in the Secondary Hyperparathyroidism pipeline products market are OPKO Health Inc, Shaanxi Micot Technology Co Ltd, Amgen Inc, Cinkate Corp, Jiangsu Hengrui Medicine Co Ltd, Mitsubishi Tanabe Pharma Corp, Novadiol Inc, Scohia Pharma Inc, TaiRx Inc, and Vidasym Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.